Abstract | BACKGROUND: METHODS: Comprehensive CV safety analyses were performed in 4 clinical studies of naloxegol (12.5 and/or 25 mg) in patients with noncancer pain and OIC: two 12-week, double-blind, randomized studies; a 12-week, double-blind, extension study; and a 52-week, randomized, open-label study versus usual care. Evaluations of baseline CV risk were obtained from medical histories and clinical findings at the time of study initiation. RESULTS: Across the 4 studies (N = 2135), 68% of patients had ≥1 CV risk factor and 41% had a history of CV disease, diabetes, or ≥2 other CV risk factors. There were no increases in blood pressure, heart rate, or the rate-pressure product with naloxegol versus placebo. The rates of major adverse cardiovascular events ( MACE) per 100 patient-years of exposure were 1.13 (95% confidence interval [CI], 0.31-2.89) for placebo/usual care and 0.75 (95% CI, 0.24-1.75) for naloxegol. The relative risk of MACE for all doses of naloxegol versus placebo was 0.67 (95% CI, 0.14-3.36). CONCLUSION: These data demonstrate that naloxegol has a CV safety profile comparable to placebo/usual care in patients with OIC. Although the observed number of events was low, the data show no CV signal in patients with OIC treated with naloxegol.
|
Authors | William B White, Peter Kowey, Ulysses Diva, Mark Sostek, Raj Tummala |
Journal | Journal of cardiovascular pharmacology and therapeutics
(J Cardiovasc Pharmacol Ther)
Vol. 23
Issue 4
Pg. 309-317
(07 2018)
ISSN: 1940-4034 [Electronic] United States |
PMID | 29504415
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Analgesics, Opioid
- Morphinans
- Narcotic Antagonists
- Receptors, Opioid, mu
- Polyethylene Glycols
- naloxegol
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Analgesics, Opioid
(adverse effects)
- Cardiovascular System
(drug effects, metabolism, physiopathology)
- Chronic Pain
(drug therapy)
- Clinical Trials, Phase III as Topic
- Constipation
(chemically induced, drug therapy, metabolism, physiopathology)
- Defecation
(drug effects)
- Evidence-Based Medicine
(methods)
- Female
- Humans
- Male
- Middle Aged
- Morphinans
(adverse effects, therapeutic use)
- Narcotic Antagonists
(adverse effects, therapeutic use)
- Polyethylene Glycols
(adverse effects, therapeutic use)
- Randomized Controlled Trials as Topic
- Receptors, Opioid, mu
(antagonists & inhibitors, metabolism)
- Recovery of Function
- Risk Assessment
- Risk Factors
- Signal Transduction
(drug effects)
- Treatment Outcome
- Young Adult
|